Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) Equity Average: 2021-2025

Historic Equity Average for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to $111.3 million.

  • Prime Medicine's Equity Average fell 42.32% to $111.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.3 million, marking a year-over-year decrease of 42.32%. This contributed to the annual value of $143.1 million for FY2024, which is 36.30% down from last year.
  • As of Q3 2025, Prime Medicine's Equity Average stood at $111.3 million, which was up 32.72% from $83.9 million recorded in Q2 2025.
  • Prime Medicine's 5-year Equity Average high stood at $297.5 million for Q1 2023, and its period low was -$209.1 million during Q3 2022.
  • Moreover, its 3-year median value for Equity Average was $188.4 million (2024), whereas its average is $185.1 million.
  • In the last 5 years, Prime Medicine's Equity Average surged by 284.13% in 2023 and then tumbled by 61.90% in 2025.
  • Prime Medicine's Equity Average (Quarterly) stood at -$125.3 million in 2021, then soared by 137.17% to $46.6 million in 2022, then soared by 250.99% to $163.5 million in 2023, then grew by 4.78% to $171.3 million in 2024, then crashed by 42.32% to $111.3 million in 2025.
  • Its last three reported values are $111.3 million in Q3 2025, $83.9 million for Q2 2025, and $130.0 million during Q1 2025.